Report Library
All Reports
Post-AASLD Hepatitis C Survey
December 16, 2014
Following our live coverage of AASLD, we surveyed 27 US and 22 EU physicians regarding their current Hepatitis C treatment practices
and their
future plans given newly approved DAA treatment regimens. The results of this survey reveal differences in current treatment and
reimbursement strategies between the US and EU.
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
To view the full Post-AASLD Hepatitis C Survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
To view the full Post-AASLD Hepatitis C Survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Hepatitis C (HCV) (Antiviral) |
Additional Resources: